Physician profile
Carol Cantrell
NPI 1417996117
$843.01
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $211 · 2020: $262 · 2021: $301 · 2022: $68.05.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $156.54 | 2020-2022 | |
| Novo Nordisk INC | $144.56 | 2019-2020 | |
| Lilly USA, LLC | $122.45 | 2020-2021 | |
| Pfizer INC. | $105.00 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $68.82 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $51.13 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $34.91 | 2019-2020 | |
| Collegium Pharmaceutical, INC. | $33.45 | 2019-2021 | |
| Eisai INC. | $26.29 | 2020 | |
| Sanofi-Aventis U.S. LLC | $18.89 | 2019 | |
| Biogen, INC. | $18.22 | 2021 | |
| Abbott Laboratories | $17.94 | 2021 | |
| Almatica Pharma LLC | $15.37 | 2021 | |
| Amgen INC. | $15.04 | 2019 | |
| Allergan, INC. | $14.40 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carol Cantrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.